Cd133 Is An Independent Predictive And Prognostic Marker In Metastatic Breast Cancer Ios Press

Prognostic Significance Of CD133 Enriched In Gastric Cancer, Lung... | Download Scientific Diagram

Prognostic Significance Of CD133 Enriched In Gastric Cancer, Lung... | Download Scientific Diagram Objectives: to evaluate the impact of immunohistochemical expression of cd133 on response rate and survival in metastatic breast cancer, as well as to correlate it with various demographics and clinicopathological characteristics. To evaluate the impact of immunohistochemical expression of cd133 on response rate and survival in metastatic breast cancer, as well as to correlate it with various demographics and clinicopathological characteristics.

(PDF) Prognostic Value Of Cancer Stem Cell Marker CD133 Expression In Gastric Cancer: A ...

(PDF) Prognostic Value Of Cancer Stem Cell Marker CD133 Expression In Gastric Cancer: A ... Objectives: to evaluate the impact of immunohistochemical expression of cd133 on response rate and survival in metastatic breast cancer, as well as to correlate it with various demographics and clinicopathological characteristics. Abstract: background: cd133 is a transmembrane glycoprotein and is considered the most common cell surface marker to identify cancer stem cells in hematological and solid tumors, including breast cancer. In this review, we summarize the latest findings about the implication of cd133 in breast tumors, highlighting its role in tumor cells with a triple negative phenotype in which it directly regulates the expression of proteins involved in metastasis and drug resistance. Cd133 protein is a widely used marker for isolating cancer stem cell (csc). its expression is associated with the prognosis of many cancers. however, whether cd133 mrna could be used as an independent prognostic factor for breast cancer remains inconsistent in previous studies.

CD133 Is Clinically Significant In Lung Cancer But Not Breast Cancer... | Download Scientific ...

CD133 Is Clinically Significant In Lung Cancer But Not Breast Cancer... | Download Scientific ... In this review, we summarize the latest findings about the implication of cd133 in breast tumors, highlighting its role in tumor cells with a triple negative phenotype in which it directly regulates the expression of proteins involved in metastasis and drug resistance. Cd133 protein is a widely used marker for isolating cancer stem cell (csc). its expression is associated with the prognosis of many cancers. however, whether cd133 mrna could be used as an independent prognostic factor for breast cancer remains inconsistent in previous studies. In view of the inconsistent conclusions on the impact of cd133 expression in breast cancer patients, it was necessary to conduct a meta analysis to evaluate the prognostic value of cd133 in breast cancer. Recent clinical studies have shown that high expression of cd133 in tumors has been indicated as a prognostic marker of disease progression. as such, a spectrum of immunotherapeutic strategies have been developed to target these cd133 pos cells with the goal of translation into the clinic. Secondary objectives included assessing the combined utility of cd133 expression in ctcs and cea levels for prognostic evaluation and exploring the associations between cd133 positive ctcs and clinicopathological factors, such as tumor stage, grade, and metastatic potential. Background/aim: this study aimed to examine the clinical significance of the protein expression of the cancer stem cell (csc) markers aldh1a1, cd133, cd44, and msi 1 in primary and metastatic tissues of patients with breast cancer (bc).

CD133 Is An Independent Predictive And Prognostic Marker In Metastatic Breast Cancer - IOS Press

CD133 Is An Independent Predictive And Prognostic Marker In Metastatic Breast Cancer - IOS Press In view of the inconsistent conclusions on the impact of cd133 expression in breast cancer patients, it was necessary to conduct a meta analysis to evaluate the prognostic value of cd133 in breast cancer. Recent clinical studies have shown that high expression of cd133 in tumors has been indicated as a prognostic marker of disease progression. as such, a spectrum of immunotherapeutic strategies have been developed to target these cd133 pos cells with the goal of translation into the clinic. Secondary objectives included assessing the combined utility of cd133 expression in ctcs and cea levels for prognostic evaluation and exploring the associations between cd133 positive ctcs and clinicopathological factors, such as tumor stage, grade, and metastatic potential. Background/aim: this study aimed to examine the clinical significance of the protein expression of the cancer stem cell (csc) markers aldh1a1, cd133, cd44, and msi 1 in primary and metastatic tissues of patients with breast cancer (bc).

Imaging cancer stem cell antigen CD133 with a novel zirconium-89 labelled antibody